UNSPSC 51281910: Nemorubicin hydrochloride

This classification denotes an anthracycline antibiotic C32H37NO13.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2Q6F8JYX76, chemically known as 5,12-naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-((2,3,6-trideoxy-3-((2s)-2-methoxy-4-morpholinyl)-.alpha.-l-lyxo-hexopyranosyl)oxy)-, hydrochloride, (8s,10s)-, but more generally known as nemorubicin hydrochloride, which bears US NIH Compound Identifier 56840906.

UNSPSC 51281910 Nemorubicin hydrochloride is a Commodity code representing a specific pharmaceutical product used in oncology treatment. State and local procurement activity under this code centers on pharmaceutical acquisition for health plans, employee benefits programs, and government health systems that cover cancer therapeutics. The issuing bodies soliciting under this code are primarily state health and human services departments managing pharmacy benefit programs for public employees, Medicaid beneficiaries, and other covered populations. Procurement mechanisms include both direct pharmaceutical purchasing and indirect acquisition through pharmacy benefit managers, group purchasing organizations, and direct-to-manufacturer arrangements that allow health systems to negotiate pricing and volume commitments outside traditional wholesale channels.

Texas Health and Human Services Commission posted Request for Information No. HHS0017013 on April 3, 2026, seeking vendor capabilities for implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The RFI solicits information from potential vendors and stakeholders about establishing direct relationships between the state's pharmacy benefit program and pharmaceutical manufacturers to improve prescription fulfillment efficiency and cost management. The state seeks vendor experience with direct contracting for self-insured employers and health plans in both private and government sectors, flexibility to negotiate contracts using negotiated net pricing models without rebates, and capability to implement value-based or outcomes-based agreements. No formal award value, budget range, or set-aside designations are specified in the current RFI materials, as the state is conducting foundational market research on available solutions before issuing a formal Request for Proposal with established financial and temporal parameters.